BEXIMCO PHARMACEUTICALS LTD.
Allergic disease or symptoms such as urticaria, pruritus of various origin, eczema, itching, drug rash, insect bites, allergic conjunctivitis, dermatitis of nutritional origin, hay fever, vasomotor rhinitis, allergic asthma.
Mebhydrolin is an ethylenediamine derivative antihistamine with antimuscarinic and sedative properties.
Adult: 100-300 mg/day or 2-6 tablets daily. Child: 2-5 year: 50-150 mg/day or 1-3 tablets daily; 5-10 year: 100-200 mg/day or 2-4 tablets daily; >10 year: 100-300 mg/day or 2-6 tablets daily. Treatment should be given in several single doses daily. Mebhydrolin may be swallowed during or shortly after meals. For children, the tablet may be crushed and mixed with food.
Enhanced sedation with alcohol or other CNS depressants. Additive antimuscarinic effects with MAOIs, atropine, TCAs. May mask warning symptoms caused by ototoxic agents e.g. aminoglycoside antibiotics.
Hypersensitivity to any of the ingredients of Mebhydrolin tablet or to mebhydrolin, prostatic hypertrophy, narrow-angle glaucoma, first trimester of pregnancy
Lassitude, dizziness, hypotension, muscular weakness, nausea, vomiting, diarrhoea or constipation, epigastric pain, headache, blurred vision, tinnitus, depression, nightmares, anorexia, dryness of the mouth, tightness of the chest, tingling, sedation, drowsiness etc. may occur.
Safety in pregnancy and lactation has not been established.
Closed-angle glaucoma; urinary retention, prostatic hyperplasia or pyloroduodenal obstruction; epilepsy. Elderly. Pregnancy. May impair ability to drive or operate machinery.
Store below 258 C.